Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes : An Individual-Participant Data Meta-Analysis
Importance: Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US.
Objective: To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes.
Design, Setting, and Participants: Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021.
Exposures: The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR).
Main Outcomes and Measures: The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses.
Results: Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associated with higher risk for each of the 10 adverse outcomes, including those in the mildest categories of chronic kidney disease. For example, among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m2 based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m2 (adjusted hazard ratio, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]).
Conclusions and Relevance: In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:330 |
|---|---|
| Enthalten in: |
JAMA - 330(2023), 13 vom: 03. Okt., Seite 1266-1277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Writing Group for the CKD Prognosis Consortium [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AYI8EX34EU |
|---|
| Anmerkungen: |
Date Completed 05.10.2023 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1001/jama.2023.17002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362815801 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362815801 | ||
| 003 | DE-627 | ||
| 005 | 20240426233317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2023.17002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM362815801 | ||
| 035 | |a (NLM)37787795 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Writing Group for the CKD Prognosis Consortium |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes |b An Individual-Participant Data Meta-Analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US | ||
| 520 | |a Objective: To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes | ||
| 520 | |a Design, Setting, and Participants: Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021 | ||
| 520 | |a Exposures: The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR) | ||
| 520 | |a Main Outcomes and Measures: The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses | ||
| 520 | |a Results: Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associated with higher risk for each of the 10 adverse outcomes, including those in the mildest categories of chronic kidney disease. For example, among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m2 based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m2 (adjusted hazard ratio, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]) | ||
| 520 | |a Conclusions and Relevance: In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 650 | 7 | |a Cystatin C |2 NLM | |
| 650 | 7 | |a Albumins |2 NLM | |
| 700 | 1 | |a Grams, Morgan E |e verfasserin |4 aut | |
| 700 | 1 | |a Coresh, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Matsushita, Kunihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ballew, Shoshana H |e verfasserin |4 aut | |
| 700 | 1 | |a Sang, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Surapaneni, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Alencar de Pinho, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Lawrence J |e verfasserin |4 aut | |
| 700 | 1 | |a Ärnlöv, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Fereidoun |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Bilo, Henk J G |e verfasserin |4 aut | |
| 700 | 1 | |a Brunskill, Nigel J |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero, Juan J |e verfasserin |4 aut | |
| 700 | 1 | |a Chadban, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Chalmers, John |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ciemins, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Cirillo, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ebert, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreiro, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Edouard L |e verfasserin |4 aut | |
| 700 | 1 | |a Fukagawa, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Jamie A |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Orlando M |e verfasserin |4 aut | |
| 700 | 1 | |a Herrington, William G |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Shih-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Inker, Lesley A |e verfasserin |4 aut | |
| 700 | 1 | |a Iseki, Kunitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Jafar, Tazeen |e verfasserin |4 aut | |
| 700 | 1 | |a Jassal, Simerjot K |e verfasserin |4 aut | |
| 700 | 1 | |a Jha, Vivekanand |e verfasserin |4 aut | |
| 700 | 1 | |a Kadota, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Köttgen, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Konta, Tsuneo |e verfasserin |4 aut | |
| 700 | 1 | |a Kronenberg, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Brian J |e verfasserin |4 aut | |
| 700 | 1 | |a Lees, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Adeera |e verfasserin |4 aut | |
| 700 | 1 | |a Looker, Helen C |e verfasserin |4 aut | |
| 700 | 1 | |a Major, Rupert |e verfasserin |4 aut | |
| 700 | 1 | |a Melzer Cohen, Cheli |e verfasserin |4 aut | |
| 700 | 1 | |a Mieno, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Mariko |e verfasserin |4 aut | |
| 700 | 1 | |a Moranne, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Muraki, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Naimark, David |e verfasserin |4 aut | |
| 700 | 1 | |a Nitsch, Dorothea |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Wonsuk |e verfasserin |4 aut | |
| 700 | 1 | |a Pena, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Purnell, Tanjala S |e verfasserin |4 aut | |
| 700 | 1 | |a Sabanayagam, Charumathi |e verfasserin |4 aut | |
| 700 | 1 | |a Satoh, Michihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sawhney, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Schaeffner, Elke |e verfasserin |4 aut | |
| 700 | 1 | |a Schöttker, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jenny I |e verfasserin |4 aut | |
| 700 | 1 | |a Shlipak, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Smeeta |e verfasserin |4 aut | |
| 700 | 1 | |a Stengel, Benedicte |e verfasserin |4 aut | |
| 700 | 1 | |a Sumida, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tonelli, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Valdivielso, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a van Zuilen, Arjan D |e verfasserin |4 aut | |
| 700 | 1 | |a Visseren, Frank L J |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Angela Yee-Moon |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Chi-Pang |e verfasserin |4 aut | |
| 700 | 1 | |a Wheeler, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Yatsuya, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamagata, Kunihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haitao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Luxia |e verfasserin |4 aut | |
| 700 | 1 | |a Levey, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Gansevoort, Ron T |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Lawrence J |e investigator |4 oth | |
| 700 | 1 | |a Grams, Morgan |e investigator |4 oth | |
| 700 | 1 | |a Woodward, Mark |e investigator |4 oth | |
| 700 | 1 | |a Harris, Katie |e investigator |4 oth | |
| 700 | 1 | |a Arima, Hisatomi |e investigator |4 oth | |
| 700 | 1 | |a Chalmers, John |e investigator |4 oth | |
| 700 | 1 | |a Yatsuya, Hiroshi |e investigator |4 oth | |
| 700 | 1 | |a Tamakoshi, Koji |e investigator |4 oth | |
| 700 | 1 | |a Li, Yuanying |e investigator |4 oth | |
| 700 | 1 | |a Coresh, Josef |e investigator |4 oth | |
| 700 | 1 | |a Sang, Yingying |e investigator |4 oth | |
| 700 | 1 | |a Matsushita, Kunihiro |e investigator |4 oth | |
| 700 | 1 | |a Polkinghorne, Kevan |e investigator |4 oth | |
| 700 | 1 | |a Chadban, Steve |e investigator |4 oth | |
| 700 | 1 | |a Levin, Adeera |e investigator |4 oth | |
| 700 | 1 | |a Djurdjev, Ognjenka |e investigator |4 oth | |
| 700 | 1 | |a Tang, Mila |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Luxia |e investigator |4 oth | |
| 700 | 1 | |a Wang, Fang |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jinwei |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Ming-Hui |e investigator |4 oth | |
| 700 | 1 | |a Schaeffner, Elke |e investigator |4 oth | |
| 700 | 1 | |a Ebert, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Mielke, Nina |e investigator |4 oth | |
| 700 | 1 | |a Tonelli, Marcello |e investigator |4 oth | |
| 700 | 1 | |a Lloyd, Anita |e investigator |4 oth | |
| 700 | 1 | |a Sacks, Frank |e investigator |4 oth | |
| 700 | 1 | |a Shlipak, Michael G |e investigator |4 oth | |
| 700 | 1 | |a Bansal, Nisha |e investigator |4 oth | |
| 700 | 1 | |a Sarnak, Mark |e investigator |4 oth | |
| 700 | 1 | |a Yamagishi, Kazumasa |e investigator |4 oth | |
| 700 | 1 | |a Muraki, Isao |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, Yuji |e investigator |4 oth | |
| 700 | 1 | |a Iso, Hiroyasu |e investigator |4 oth | |
| 700 | 1 | |a Fukagawa, Masafumi |e investigator |4 oth | |
| 700 | 1 | |a Maruyama, Shoichi |e investigator |4 oth | |
| 700 | 1 | |a Hamano, Takayuki |e investigator |4 oth | |
| 700 | 1 | |a Fujii, Naohiko |e investigator |4 oth | |
| 700 | 1 | |a Imaizumi, Takahiro |e investigator |4 oth | |
| 700 | 1 | |a Alencar De Pinho, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Metzger, Marie |e investigator |4 oth | |
| 700 | 1 | |a Stengel, Bénédicte |e investigator |4 oth | |
| 700 | 1 | |a Hamroun, Aghilès |e investigator |4 oth | |
| 700 | 1 | |a Massy, Ziad |e investigator |4 oth | |
| 700 | 1 | |a Jafar, Tazeen H |e investigator |4 oth | |
| 700 | 1 | |a Jehan, Imtiaz |e investigator |4 oth | |
| 700 | 1 | |a Hatcher, Juanita |e investigator |4 oth | |
| 700 | 1 | |a Chaturvedi, Nish |e investigator |4 oth | |
| 700 | 1 | |a Poulter, Neil |e investigator |4 oth | |
| 700 | 1 | |a Wheeler, David C |e investigator |4 oth | |
| 700 | 1 | |a Landray, Martin |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jing |e investigator |4 oth | |
| 700 | 1 | |a Lash, James |e investigator |4 oth | |
| 700 | 1 | |a Taliercio, Jon |e investigator |4 oth | |
| 700 | 1 | |a Yang, Peter Wei |e investigator |4 oth | |
| 700 | 1 | |a Tuttle, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Alicic, Radica |e investigator |4 oth | |
| 700 | 1 | |a Nicholas, Susanne |e investigator |4 oth | |
| 700 | 1 | |a Shen, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Schöttker, Ben |e investigator |4 oth | |
| 700 | 1 | |a Stocker, Hannah |e investigator |4 oth | |
| 700 | 1 | |a Rothenbacher, Dietrich |e investigator |4 oth | |
| 700 | 1 | |a Brenner, Hermann |e investigator |4 oth | |
| 700 | 1 | |a Levy, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Hwang, Shih-Jen |e investigator |4 oth | |
| 700 | 1 | |a Schneider, Markus P |e investigator |4 oth | |
| 700 | 1 | |a Köttgen, Anna |e investigator |4 oth | |
| 700 | 1 | |a Meiselbach, Heike |e investigator |4 oth | |
| 700 | 1 | |a Eckardt, Kai-Uwe |e investigator |4 oth | |
| 700 | 1 | |a Chang, Alexander R |e investigator |4 oth | |
| 700 | 1 | |a Green, Jamie A |e investigator |4 oth | |
| 700 | 1 | |a Kirchner, H Lester |e investigator |4 oth | |
| 700 | 1 | |a Singh, Gurmukteshwar |e investigator |4 oth | |
| 700 | 1 | |a Sawhney, Simon |e investigator |4 oth | |
| 700 | 1 | |a Black, Corri |e investigator |4 oth | |
| 700 | 1 | |a Wilde, Katie |e investigator |4 oth | |
| 700 | 1 | |a Marks, Angharad |e investigator |4 oth | |
| 700 | 1 | |a Bell, Samira |e investigator |4 oth | |
| 700 | 1 | |a Siddiqui, Moneeza |e investigator |4 oth | |
| 700 | 1 | |a Palmer, Colin |e investigator |4 oth | |
| 700 | 1 | |a Pearson, Ewan |e investigator |4 oth | |
| 700 | 1 | |a Miyazaki, Mariko |e investigator |4 oth | |
| 700 | 1 | |a Nakayama, Masaaki |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, Tae |e investigator |4 oth | |
| 700 | 1 | |a Yamada, Gen |e investigator |4 oth | |
| 700 | 1 | |a Ito, Sadayoshi |e investigator |4 oth | |
| 700 | 1 | |a Cirillo, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Wang, Angela Yee-Moon |e investigator |4 oth | |
| 700 | 1 | |a Wu, Henry Hon-Lin |e investigator |4 oth | |
| 700 | 1 | |a Cheung, Hoi Ching |e investigator |4 oth | |
| 700 | 1 | |a Ngai, Victoria |e investigator |4 oth | |
| 700 | 1 | |a Tak, Tang Ka |e investigator |4 oth | |
| 700 | 1 | |a Garg, Amit X |e investigator |4 oth | |
| 700 | 1 | |a McArthur, Eric |e investigator |4 oth | |
| 700 | 1 | |a Young, Ann |e investigator |4 oth | |
| 700 | 1 | |a Jha, Vivekanand |e investigator |4 oth | |
| 700 | 1 | |a Yadav, Ashok Kumar |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Vivek |e investigator |4 oth | |
| 700 | 1 | |a Carson, April P |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA |d 1948 |g 330(2023), 13 vom: 03. Okt., Seite 1266-1277 |w (DE-627)NLM000006939 |x 1538-3598 |7 nnns |
| 773 | 1 | 8 | |g volume:330 |g year:2023 |g number:13 |g day:03 |g month:10 |g pages:1266-1277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2023.17002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 330 |j 2023 |e 13 |b 03 |c 10 |h 1266-1277 | ||